3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
8
Head & Neck
5
Genitourinary
3
Breast
3
Thoracic
2
Gastrointestinal
2
Myeloid
1
Lymphoid
1
Gynecologic
1
Dermatologic
1
CNS
1
Conditions
Melanoma
7
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
3
Skin Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Stomach Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Glioma
1
Endometrial Neoplasms
1
Carcinoma, Hepatocellular
1
Adenocarcinoma of Lung
1
Interventions
Cyclophosphamide
16
pembrolizumab
14
Radiosurgery
7
Nivolumab
5
Celecoxib
5
poly ICLC
4
Radiation
4
Injections
4
Radiotherapy
3
Melphalan
3
Ipilimumab
3
Filgrastim
3
Etoposide
3
Docetaxel
3
Cryosurgery
3
Blood Specimen Collection
3
Biopsy
3
130-nm albumin-bound paclitaxel
3
trastuzumab deruxtecan
2
tislelizumab
2
talimogene laherparepvec
2
spartalizumab
2
fludarabine phosphate
2
fludarabine
2
durvalumab
2
cemiplimab
2
atezolizumab
2
aldesleukin
2
Transurethral Resection of Prostate
2
Therapeutics
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
Cetuximab
×
Dermatologic
×
Clear all
NCT03009058
2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2
Terminated
2 enrolled
7 charts